| Literature DB >> 28947377 |
D Andrew Wilkinson1, Aditya S Pandey2, B Gregory Thompson2, Richard F Keep2, Ya Hua2, Guohua Xi3.
Abstract
Intracerebral hemorrhage (ICH) is the most common hemorrhagic stroke subtype, and rates are increasing with an aging population. Despite an increase in research and trials of therapies for ICH, mortality remains high and no interventional therapy has been demonstrated to improve outcomes. We review known mechanisms of injury, recent clinical trial results, and newly discovered signaling pathways involved in hematoma clearance. Enthusiasm remains high for methods of minimally invasive clot removal as well as pharmacologic strategies to improve recovery after ICH, both of which are currently being evaluated in clinical trials. This article is part of the Special Issue entitled 'Cerebral Ischemia'.Entities:
Keywords: Brain edema; Hematoma; Hypertension; Intracerebral hemorrhage; Iron; Thrombin
Mesh:
Year: 2017 PMID: 28947377 PMCID: PMC6027647 DOI: 10.1016/j.neuropharm.2017.09.033
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250